Difference between revisions of "Part:BBa K5302010"
| Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
| − | <partinfo> | + | <partinfo>BBa_K5302010 short</partinfo> |
This part is a cyclic peptide (known as VGB1) reproducing the α1 helix and its adjacent region based on the X-ray structure of VEGF-B/VEGFR1D2, he sequence of the designed 17-amino acid peptide (referred to as VGB1) was 2HN-CSWIDVYTRATCQPRPL-COOH. It exhibits high affinity for VEGFR-like receptors, allowing it to effectively compete with VEGF for binding to VEGFR. Consequently, this peptide has been utilized as a masking agent. Upon administration into the human body, it preemptively binds to VEGFR, preventing VEGF from engaging with the receptor. | This part is a cyclic peptide (known as VGB1) reproducing the α1 helix and its adjacent region based on the X-ray structure of VEGF-B/VEGFR1D2, he sequence of the designed 17-amino acid peptide (referred to as VGB1) was 2HN-CSWIDVYTRATCQPRPL-COOH. It exhibits high affinity for VEGFR-like receptors, allowing it to effectively compete with VEGF for binding to VEGFR. Consequently, this peptide has been utilized as a masking agent. Upon administration into the human body, it preemptively binds to VEGFR, preventing VEGF from engaging with the receptor. | ||
| Line 12: | Line 12: | ||
<!-- --> | <!-- --> | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
| − | <partinfo> | + | <partinfo>BBa_K5302010 SequenceAndFeatures</partinfo> |
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
===Functional Parameters=== | ===Functional Parameters=== | ||
| − | <partinfo> | + | <partinfo>BBa_K5302010 parameters</partinfo> |
<!-- --> | <!-- --> | ||
Revision as of 05:22, 1 October 2024
VGB
This part is a cyclic peptide (known as VGB1) reproducing the α1 helix and its adjacent region based on the X-ray structure of VEGF-B/VEGFR1D2, he sequence of the designed 17-amino acid peptide (referred to as VGB1) was 2HN-CSWIDVYTRATCQPRPL-COOH. It exhibits high affinity for VEGFR-like receptors, allowing it to effectively compete with VEGF for binding to VEGFR. Consequently, this peptide has been utilized as a masking agent. Upon administration into the human body, it preemptively binds to VEGFR, preventing VEGF from engaging with the receptor. Given that matrix metalloproteinases (MMPs) are present at high concentrations in the tumor microenvironment (TME), they can degrade this VEGFR-masking peptide (designated as #29). This degradation allows VEGF to subsequently bind to the VEGFR-like receptors, triggering their activation. Therefore, this peptide functions as a biological switch, becoming active when exposed to the TME upon the entry of engineered chimeric nanoparticles ( Escherichia coli Nissle 1917).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]